Immune Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 12, 2021 at 10:29 am EST
Share
Immune Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net income was USD 3.11 million compared to USD 4.09 million a year ago. Basic earnings per share from continuing operations was USD 6.44 compared to USD 8.95 a year ago. Diluted earnings per share from continuing operations was USD 0.24 compared to USD 0.24 a year ago.
For the nine months, net income was USD 3.79 million compared to USD 2.5 million a year ago. Basic earnings per share from continuing operations was USD 7.86 compared to USD 5.46 a year ago. Diluted earnings per share from continuing operations was USD 0.29 compared to USD 0.17 a year ago.
Biostax Corp. is a developer and marketer of pharmaceutical, biotechnology, and MedTech products. The Company has partnerships in the fields of autoimmunity and immune restoration and are able to deliver solutions today for people that are living with autoimmunity, chronic inflammation, infection, and cancer. Its internal and partner programs comprised of JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that has demonstrated anti-fibrotic, immuno-modulating, and anti-inflammatory activities in preclinical models; Lodonal, is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), and LDN, which is a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging.